In vitro activity of aminosterols against yeasts involved in blood stream infections

Medical Mycology

Volumn 49, Issue 2, 2011, Pages 121-125

  Alhanout, Kamel ^a   Djouhri, Lamia ^a   Vidal, Nicolas ^b   Brunel, Jean Michel ^a   Piarroux, Renaud ^c   Ranque, Stéphane ^a,c  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c Laboratoire de Parasitologie Mycologie   (France)

Author keywords

antifungal; resistance; Squalamine; therapy

Indexed keywords

AMINOSTEROL DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; SQUALAMINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG SAFETY; FUNGEMIA; HEMOLYSIS; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHIA GUILLIERMONDII;

ADENOSINE TRIPHOSPHATE; ANTIFUNGAL AGENTS; CHOLESTANOLS; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TIME FACTORS; YEASTS;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 78751520932     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.502189     Document Type: Article

References (18)

1. Brunel JM, Salmi C, Loncle C, et al. Squalamine: a polyvalent drug of the future? Curr Cancer Drug Targets 2005; 5 : 267-272.
2. Salmi C, Brunel JM. Therapeutic potential of cationic steroid antibacterials. Expert Opin Investig Drugs 2007 ; 16 : 1143-1157.
3. Herbst RS, Hammond LA, Carbone DP, et al. A phase I/IIA trial of continuous fi ve-day infusion of squalamine lactate [MSI-1256F] plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 15 : 4108-4115.
4. Alhanout K, Brunel JM, Raoult D, et al. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fi brosis. J Antimicrob Chemother 2009; 64 : 810-814.
5. Salmi C, Loncle C, Vidal N, et al. Squalamine: an appropriate strategy against the emergence of multidrug resistant gram-negative bacteria? PLoS ONE 2008; 3 : e2765.
6. Fisher BT, Zaoutis TE. Treatment of invasive candidiasis in immunocompromised pediatric patients. Paediatr Drugs 2008; 10 : 281-298.
7. Klepser ME. Candida resistance and its clinical relevance. P harmacotherapy 2006; 26 : 68-75.
8. Krcmery V, Barnes AJ. Non-albicans C andida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50 : 243-260.
9. Montravers P, Jabbour K. Clinical consequences of resistant C andida infections in intensive care. Int J Antimicrob Agents 2006; 27 : 1-6.
10. Salmi C, Loncle C, Vidal N, et al. Antimicrobial activities of 3-amino- and polyaminosterol analogues of squalamine and trodusquemine. J Enzyme Inhib Med Chem 2008; 23 : 860-865.
11. Pryce TM, Palladino S, Kay ID, et al. Rapid identifi cation of fungi by sequencing the ITS1 and ITS2 regions using an automated capillary electrophoresis system. Med Myco 2003; 41 : 369-381.
12. NCCLS WPU2. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved Standard M27-A2. Drug Chem Toxicol 2002; 32 : 283-292.
13. Leszczynska K, Namiot A, Fein DE, et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 2009; 9 : 187.
14. Izgu F, Altinbay D, Tureli AE. In vitro susceptibilities of C andida spp. to Panomycocin, a novel exo-beta-1,3-glucanase isolated from Pichia anomala NCYC 434. Microbiol Immunol 2007; 51 : 797-803.
15. Pfaller MA, Messer SA, Boyken L, et al. I n vitro activities of voriconazole, posaconazole, and fl uconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48 : 201-205.
16. Kikuchi K, Bernard EM, Sadownik A, et al. Antimicrobial activities of squalamine mimics. Antimicrob Agents Chemother 1997; 41 : 1433-1438.
17. Chin JN, Jones RN, Sader HS, et al. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa , including multidrug-resistant P. aeruginosa . J Antimicrob Chemother 2008; 61 : 365-370.
18. Nogueira RC, Oliveira-Costa JF, de Sa MS, et al. Early toxicity screening and selection of lead compounds for parasitic diseases. Curr Drug Targets 2009; 10 : 291-298.